Published in Br J Haematol on June 01, 2002
DNA polymorphisms and response to treatment in patients with chronic hepatitis C: results from the HALT-C trial. J Hepatol (2008) 1.71
Interleukin-10 polymorphisms, cancer susceptibility and prognosis. Fam Cancer (2006) 1.08
A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron (2011) 18.73
Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17. Nature (2006) 11.59
International staging system for multiple myeloma. J Clin Oncol (2005) 11.29
Revised international prognostic scoring system for myelodysplastic syndromes. Blood (2012) 8.12
Clinical and biological implications of driver mutations in myelodysplastic syndromes. Blood (2013) 6.50
Frequency of the C9orf72 hexanucleotide repeat expansion in patients with amyotrophic lateral sclerosis and frontotemporal dementia: a cross-sectional study. Lancet Neurol (2012) 5.18
A genome-wide association study identifies six susceptibility loci for chronic lymphocytic leukemia. Nat Genet (2008) 4.37
Genetic variation in TNF and IL10 and risk of non-Hodgkin lymphoma: a report from the InterLymph Consortium. Lancet Oncol (2006) 4.13
Distinct clinical and pathological characteristics of frontotemporal dementia associated with C9ORF72 mutations. Brain (2012) 3.43
Coexistence of LMPP-like and GMP-like leukemia stem cells in acute myeloid leukemia. Cancer Cell (2011) 3.12
Aspirin for everyone older than 50? For. BMJ (2005) 3.02
Effectiveness of an early supplementation scheme of high-dose vitamin A versus standard WHO protocol in Gambian mothers and infants: a randomised controlled trial. Lancet (2007) 3.01
Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet. Blood (2013) 2.97
Mcl-1 expression has in vitro and in vivo significance in chronic lymphocytic leukemia and is associated with other poor prognostic markers. Blood (2008) 2.88
Common variants at 2q37.3, 8q24.21, 15q21.3 and 16q24.1 influence chronic lymphocytic leukemia risk. Nat Genet (2010) 2.45
Antimyeloma activity of heat shock protein-90 inhibition. Blood (2005) 2.24
Aspirin, salicylates, and cancer. Lancet (2009) 2.17
Telomere dysfunction and fusion during the progression of chronic lymphocytic leukemia: evidence for a telomere crisis. Blood (2010) 2.16
Guidelines for the diagnosis and management of multiple myeloma 2011. Br J Haematol (2011) 2.14
Molecular basis of the spectral expression of CIAS1 mutations associated with phagocytic cell-mediated autoinflammatory disorders CINCA/NOMID, MWS, and FCU. Blood (2003) 2.11
Early mortality after diagnosis of multiple myeloma: analysis of patients entered onto the United kingdom Medical Research Council trials between 1980 and 2002--Medical Research Council Adult Leukaemia Working Party. J Clin Oncol (2005) 1.97
CD49d is the strongest flow cytometry-based predictor of overall survival in chronic lymphocytic leukemia. J Clin Oncol (2014) 1.92
Myeloma management guidelines: a consensus report from the Scientific Advisors of the International Myeloma Foundation. Hematol J (2003) 1.81
Defining the pathogenic role of telomerase mutations in myelodysplastic syndrome and acute myeloid leukemia. Hum Mutat (2009) 1.78
Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN). Blood (2011) 1.75
Effects of bone-targeted agents on cancer progression and mortality. J Natl Cancer Inst (2012) 1.69
European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma. Haematologica (2014) 1.57
Tumor necrosis factor SNP haplotypes are associated with iron deficiency anemia in West African children. Blood (2008) 1.56
Functional FAS promoter polymorphisms are associated with increased risk of acute myeloid leukemia. Cancer Res (2003) 1.53
The role of the iron transporter ABCB7 in refractory anemia with ring sideroblasts. PLoS One (2008) 1.52
International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation. J Clin Oncol (2014) 1.52
Treatment of relapsed and refractory multiple myeloma in the era of novel agents. Cancer Treat Rev (2010) 1.48
Preclinical evaluation of the proteasome inhibitor bortezomib in cancer therapy. Cancer Cell Int (2005) 1.46
Arsenic trioxide in patients with myelodysplastic syndromes: a phase II multicenter study. J Clin Oncol (2006) 1.43
Evidence for reduced B-cell progenitors in early (low-risk) myelodysplastic syndrome. Blood (2005) 1.41
Genomic variation in myeloma: design, content, and initial application of the Bank On A Cure SNP Panel to detect associations with progression-free survival. BMC Med (2008) 1.40
Outcome of high-dose cytarabine-based induction therapy followed by hematopoietic stem cell transplantation in acute myeloid leukemia: influence of karyotype. Leuk Lymphoma (2008) 1.39
Safety and efficacy of romiplostim in patients with lower-risk myelodysplastic syndrome and thrombocytopenia. J Clin Oncol (2009) 1.39
Clofarabine doubles the response rate in older patients with acute myeloid leukemia but does not improve survival. Blood (2013) 1.36
Polymorphisms in the thymidylate synthase and serine hydroxymethyltransferase genes and risk of adult acute lymphocytic leukemia. Blood (2002) 1.34
Clinical, pathological and genetic characterization of hereditary sensory and autonomic neuropathy type 1 (HSAN I). Brain (2005) 1.33
Dipeptide repeat proteins are present in the p62 positive inclusions in patients with frontotemporal lobar degeneration and motor neurone disease associated with expansions in C9ORF72. Acta Neuropathol Commun (2013) 1.32
IMWG consensus on maintenance therapy in multiple myeloma. Blood (2012) 1.29
No increase in age-specific incidence of myelodysplastic syndromes. Haematologica (2004) 1.27
Expansion of a CD8(+)PD-1(+) replicative senescence phenotype in early stage CLL patients is associated with inverted CD4:CD8 ratios and disease progression. Clin Cancer Res (2011) 1.25
Essential role of proline isomerization in stefin B tetramer formation. J Mol Biol (2006) 1.23
UBAP1 is a component of an endosome-specific ESCRT-I complex that is essential for MVB sorting. Curr Biol (2011) 1.19
Pathological correlates of frontotemporal lobar degeneration in the elderly. Acta Neuropathol (2010) 1.19
Interaction with vascular endothelium enhances survival in primary chronic lymphocytic leukemia cells via NF-kappaB activation and de novo gene transcription. Cancer Res (2010) 1.19
International Myeloma Working Group recommendations for the treatment of multiple myeloma-related bone disease. J Clin Oncol (2013) 1.19
The most common type of FTLD-FUS (aFTLD-U) is associated with a distinct clinical form of frontotemporal dementia but is not related to mutations in the FUS gene. Acta Neuropathol (2011) 1.18
A national DNA bank in The Gambia, West Africa, and genomic research in developing countries. Nat Genet (2004) 1.13
Expression and activity of Toll-like receptors 1-9 in the human term placenta and changes associated with labor at term. Biol Reprod (2008) 1.13
Brain distribution of dipeptide repeat proteins in frontotemporal lobar degeneration and motor neurone disease associated with expansions in C9ORF72. Acta Neuropathol Commun (2014) 1.09
Telomere dysfunction accurately predicts clinical outcome in chronic lymphocytic leukaemia, even in patients with early stage disease. Br J Haematol (2014) 1.07
Polymorphic variation in GSTP1 modulates outcome following therapy for multiple myeloma. Blood (2003) 1.05
Abnormal serum free light chain ratios are associated with poor survival and may reflect biological subgroups in patients with chronic lymphocytic leukaemia. Br J Haematol (2008) 1.05
The Hsp90 inhibitor NVP-AUY922-AG inhibits NF-κB signaling, overcomes microenvironmental cytoprotection and is highly synergistic with fludarabine in primary CLL cells. Oncotarget (2012) 1.05
Dietary supplementation with lactobacilli and bifidobacteria is well tolerated and not associated with adverse events during late pregnancy and early infancy. J Nutr (2010) 1.04
The lumicins: novel bacteriocins from Photorhabdus luminescens with similarity to the uropathogenic-specific protein (USP) from uropathogenic Escherichia coli. FEMS Microbiol Lett (2002) 1.04
Current multiple myeloma treatment strategies with novel agents: a European perspective. Oncologist (2010) 1.04
The novel nuclear factor-kappaB inhibitor LC-1 is equipotent in poor prognostic subsets of chronic lymphocytic leukemia and shows strong synergy with fludarabine. Clin Cancer Res (2008) 1.02
Practical use of azacitidine in higher-risk myelodysplastic syndromes: an expert panel opinion. Leuk Res (2010) 1.02
An intron splice acceptor polymorphism in hMSH2 and risk of leukemia after treatment with chemotherapeutic alkylating agents. Clin Cancer Res (2003) 1.02
More patent protection for medicines with a new purpose. Nature (2010) 1.02
Birth season and environmental influences on blood leucocyte and lymphocyte subpopulations in rural Gambian infants. BMC Immunol (2008) 1.01
Genes with a spike expression are clustered in chromosome (sub)bands and spike (sub)bands have a powerful prognostic value in patients with multiple myeloma. Haematologica (2011) 1.01
Atopic disease and childhood acute lymphoblastic leukemia. Int J Cancer (2003) 1.01
Guidelines for the diagnosis and management of adult myelodysplastic syndromes. Br J Haematol (2013) 0.99
Analysis of mitochondrial DNA in 104 patients with myelodysplastic syndromes. Exp Hematol (2008) 0.98
Phosphorylation and compactness of neurofilaments in multiple sclerosis: indicators of axonal pathology. Exp Neurol (2008) 0.98
A novel Cdk9 inhibitor preferentially targets tumor cells and synergizes with fludarabine. Oncotarget (2014) 0.97
A global expression-based analysis of the consequences of the t(4;14) translocation in myeloma. Clin Cancer Res (2004) 0.97
The effect of immunoglobulin VH gene mutation status and other prognostic factors on the incidence of major infections in patients with chronic lymphocytic leukemia. Cancer (2006) 0.97
Defining the prognosis of early stage chronic lymphocytic leukaemia patients. Br J Haematol (2011) 0.96
Early clinical experience with the new Amplatzer Ductal Occluder II for closure of the persistent arterial duct. Catheter Cardiovasc Interv (2009) 0.96
Monsanto Technology LLC v. Cargill: a matter of construction. Nat Biotechnol (2008) 0.95
Beta2-microglobulin is a better predictor of treatment-free survival in patients with chronic lymphocytic leukaemia if adjusted according to glomerular filtration rate. Br J Haematol (2009) 0.95
Detection of intraepithelial and stromal Langerin and CCR5 positive cells in the human endometrium: potential targets for HIV infection. PLoS One (2011) 0.95
Flavopiridol induces apoptosis in B-cell chronic lymphocytic leukaemia cells through a p38 and ERK MAP kinase-dependent mechanism. Leuk Lymphoma (2003) 0.95
Rel a is an independent biomarker of clinical outcome in chronic lymphocytic leukemia. J Clin Oncol (2009) 0.95
Mimicking the tumour microenvironment: three different co-culture systems induce a similar phenotype but distinct proliferative signals in primary chronic lymphocytic leukaemia cells. Br J Haematol (2012) 0.94
Haplotypes in the tumour necrosis factor region and myeloma. Br J Haematol (2005) 0.94
Phase I/II clinical study of Tosedostat, an inhibitor of aminopeptidases, in patients with acute myeloid leukemia and myelodysplasia. J Clin Oncol (2010) 0.93
CD49d is an independent prognostic marker that is associated with CXCR4 expression in CLL. Leuk Res (2010) 0.93
Peripheral blood or bone marrow cells in reduced-intensity or myeloablative conditioning allogeneic HLA identical sibling donor transplantation for multiple myeloma. Haematologica (2007) 0.92
European Myeloma Network: the 3rd Trialist Forum Consensus Statement from the European experts meeting on multiple myeloma. Leuk Lymphoma (2010) 0.91
Prognostic significance of combined MN1, ERG, BAALC, and EVI1 (MEBE) expression in patients with myelodysplastic syndromes. Ann Hematol (2012) 0.91
High-dose cyclophosphamide with stem cell rescue for severe rheumatoid arthritis: short-term efficacy correlates with reduction of macroscopic and histologic synovitis. Arthritis Rheum (2002) 0.90
Risk factors for acute shunt blockage in children after modified Blalock-Taussig shunt operations. Heart Vessels (2010) 0.90
A randomised trial of a remote home support programme for infants with major congenital heart disease. Heart (2012) 0.89
Efficacy and outcome of autologous transplantation in rare myelomas. Haematologica (2010) 0.89